Search

Background: Acute coronary syndrome (ACS) is the leading cause of morbidity and mortality. Presently, there is no convenient marker that can precisely expect the onset of ACS besides its prognosis. Free fatty acid receptor 2 (FFAR2) has lately been proposed to protect from heart diseases. The study aimed to assess whether the expression of FFAR2 in peripheral blood is avaluable biomarker for diagnosis of ACS and prediction of adverse cardiac events (ACEs) among ACS patients with controlled and uncontrolled DM. Methods: Peripheral venousleukocytes were collected from 281 patients,133 as control group (Group I) and 148 diabetic patients admitted with ACS (Group II). GroupII was subdivided into Group II a, 67 ACS patients with controlled blood glucose and Group IIb, 61 ACS patients with uncontrolled blood glucose. The expression level of FFAR2 was estimated by real time PCR. Results: FFAR2 expression in ACS patients was significantly lower than that in the control group. Moreover, the FFAR2 level in ACS with uncontrolled blood glucose was lowerthan that in ACS patients with controlled blood glucose level. TheROC curve analysisshowedthat FFAR2 level had excellent sensitivity and moderate specificity to identify patients at riskof having ACE. Conclusions: FFAR2 could act as a potential biomarker in diagnosis of ACS and predicting its complications. [ABSTRACT FROM AUTHOR]

Background: Peripheral artery disease (PAD) is an advanced atherosclerotic disease-causing augmented risks of hospitalization and death. So, several studies tried to detect novel biomarkers for PAD diagnosis. The study is aimed to explore the role of plasma miRNA 323b-5p and miRNA 486-5p levels to diagnose PAD. Methods: The research was performed in Medical Biochemistry & Cardiology Departments - Zagazig Faculty of Medicine. It included 100 volunteers categorized into 2 groups; Group (1): included 50 healthy volunteers served as control group with ankle brachial index (ABI) > 0.9. Group (2): included 50 PAD patients with ABI < 0.9. Plasma 323b-5p and miR 486-5p expression level were measured via real time PCR. Color Doppler was performed to calculate ABI, which was correlated with miRNA levels. Results: There was a highly significant difference between groups as regards miR 323b-5p. Furthermore, miR 486-5p expression level showed significant variance between groups. Regarding miRNA 323b-5p expression level, cutoff value was 2.55, sensitivity was 89.3% and specificity was 72.7%. Concerning miR 486-5p expression level, cutoff value was 1.92, sensitivity was 82.1% and specificity was 81.8%. As regards combined miR 323b-5p and miR 486-5p ROC curve, it was 96.4% sensitivity and 95.5% specificity. Each miRNA showed a negative correlation with ABI. Conclusion: miRNA 323B-5P and miRNA 486-5P can be a novel and potent biomarker for PAD diagnosis, particularly for risky patients. [ABSTRACT FROM AUTHOR]